Diabetes Mellitus (DM) increases the risk of developing chronic non-alcoholic liver disease, non-alcoholic steatohepatitis, and hepatocellular carcinoma. DM elevates CYP2E1, which is critically important in human health, because it increases oxidative stress, catalyzes the metabolism of carcinogens, therapeutic agents, eicosanoids, and fatty acids, reflects an altered phenotype, and is a biomarker of progressive hepatic disease development with loss of CYP2E1 expression reflecting an aggressive hepatic tumor phenotype. The mechanism(s) by which DM regulates CYP2E1 expression are unknown. Our research shows that increasing insulin decreases CYP2E1 gene transcription by ~90%, activates Akt, and increases FOXO1, 3a and 4 transcription factor phosphorylation and inactivation. Inhibition of Akt decreases FOXO1, 3a and 4 phosphorylation and reverses the insulin-mediated downregulation of CYP2E1 mRNA expression. At the translational level, insulin decreases CYP2E1 mRNA half-life by ~50%, increases CYP2E1 microRNAs -336 and -352 by 1.5- to 3-fold,.and shifts CYP2E1 mRNA from the 60S-80S untranslated fraction to the actively translated polysome fraction, which is inhibited by inhibitors of PI3K and mTOR. Transient transfection with miR-336 and -352 suppresses CYP2E1 mRNA levels. Evidence suggests that insulin regulates CYP2E1 gene transcription through Akt and translation through mTOR. In contrast, glucagon antagonizes insulin effects through cyclic nucleotides and PKA. Thus, the overall goal of this research is to understand the mechanism(s) by which insulin simultaneously regulates the transcriptional and translational expression of CYP2E1. The hypothesis of this research is that Akt and mTOR regulate CYP2E1 gene transcription and mRNA translation, respectively, which is antagonized by glucagon through PKA at the level of transcription and/or translation.
The specific aims are: 1) To establish the mechanism(s) of insulin activation of Akt on CYP2E1 gene transcription;2) To examine the mechanism(s) by which insulin activation of mTOR regulates CYP2E1 mRNA translation and miRNA translation repression or degradation;3) To establish whether glucagon, through PKA, and/or AMPK signaling, regulates CYP2E1 gene transcription;and 4) To determine the mechanism by which glucagon, through PKA and/or AMPK signaling, regulates CYP2E1 translation. Activation and inhibition of Akt and mTOR will be used, in combination with mechanistic molecular approaches, to identify the mechanism(s) which regulate CYP2E1 expression in primary cultured rat and human hepatocytes, and animals in vivo. The use of an insulin mimetic, atorvastatin and metformin are relevant to Akt signaling, insulin resistance, and clinical treatment of diabetes, while the inhibitors of Akt and mTOR are relevant to the progression and treatment of cancer. Understanding CYP2E1 regulation, as a sentinel of Akt, mTOR signaling, in the insulin regulation of gene transcription, miRNAs and mRNA translation is critical to understanding the progression of hepatic disease culminating in HCC and the role of CYP2E1 as a biomarker of this process.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES003656-19
Application #
7936920
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Carlin, Danielle J
Project Start
1988-04-01
Project End
2011-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
19
Fiscal Year
2010
Total Cost
$379,997
Indirect Cost
Name
Wayne State University
Department
Type
Organized Research Units
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Shukla, Upasana; Tumma, Nithin; Gratsch, Theresa et al. (2013) Insights into insulin-mediated regulation of CYP2E1: miR-132/-212 targeting of CYP2E1 and role of phosphatidylinositol 3-kinase, Akt (protein kinase B), mammalian target of rapamycin signaling in regulating miR-132/-212 and miR-122/-181a expression in pri Drug Metab Dispos 41:1769-77
Hudder, Alice; Novak, Raymond F (2008) miRNAs: effectors of environmental influences on gene expression and disease. Toxicol Sci 103:228-40
Kim, Sang K; Novak, Raymond F (2007) The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol Ther 113:88-120
Kim, Sang K; Abdelmegeed, Mohamed A; Novak, Raymond F (2006) Identification of the insulin signaling cascade in the regulation of alpha-class glutathione S-transferase expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther 316:1255-61
Kim, Sang K; Abdelmegeed, Mohamed A; Novak, Raymond F (2006) The mitogen-activated protein kinase kinase (mek) inhibitor PD98059 elevates primary cultured rat hepatocyte glutathione levels independent of inhibiting mek. Drug Metab Dispos 34:683-9
Abdelmegeed, Mohamed A; Carruthers, Nicholas J; Woodcroft, Kimberley J et al. (2005) Acetoacetate induces CYP2E1 protein and suppresses CYP2E1 mRNA in primary cultured rat hepatocytes. J Pharmacol Exp Ther 315:203-13
Kim, Sang K; Woodcroft, Kimberley J; Oh, Soo Jin et al. (2005) Role of mechanical and redox stress in activation of mitogen-activated protein kinases in primary cultured rat hepatocytes. Biochem Pharmacol 70:1785-95
Abdelmegeed, Mohamed A; Kim, Sang K; Woodcroft, Kimberley J et al. (2004) Acetoacetate activation of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in primary cultured rat hepatocytes: role of oxidative stress. J Pharmacol Exp Ther 310:728-36
Kim, Sang K; Woodcroft, Kimberley J; Khodadadeh, Sarah S et al. (2004) Insulin signaling regulates gamma-glutamylcysteine ligase catalytic subunit expression in primary cultured rat hepatocytes. J Pharmacol Exp Ther 311:99-108
Kim, Sang K; Woodcroft, Kimberley J; Kim, Sang G et al. (2003) Insulin and glucagon signaling in regulation of microsomal epoxide hydrolase expression in primary cultured rat hepatocytes. Drug Metab Dispos 31:1260-8

Showing the most recent 10 out of 43 publications